【摘要】 目的探讨e抗原阳性慢性乙型肝炎临床分度与拉米夫定抗病毒疗效的关系。方法选择按肝功能损伤程度分轻、中、重度e抗原阳性慢性乙型肝炎患者,各15例,均完成48周LAM 100 mg/d治疗,治疗期间定期复查肝功能、HBV标志物及HBV DNA水平,分别比较轻、中、重度三组患者在治疗3个月、6个月及1年的e抗原及HBV-DNA转阴率和ALT复常率。结果治疗3个月、6个月及1年后e抗原阳性慢性乙型肝炎轻、中、重度三组患者ALT复常率、HBV-DNA和e抗原转阴率有不同程度的改善,而中、重度二组患者HBVDNA及e抗原转阴率明显高于轻度患者(P<0.05)。结论 e抗原阳性慢性乙型肝炎中、重度对拉米夫定抗病毒疗效最好。更多还原

【Abstract】 Objective To investigate the relationship between the clinical graduation of e antigen-positive Hepatitis B and the therapeutic effect of lamivudine in anti-HBV.Methods 45 e antigen-positive patients were equal divided in to three groups:mild,moderate and severe,according to liver function lesion.All patients received on LAM 100mg/d for at least 48 weeks.The liver function,serum HBV markers and Hepatic Viral load were regularly checked during the treatment in 3,6 and 12 months.To compare the negative conversion ratios of e antigen,HBVDNA and ALT in the three groups patients above respectively.Results The three groups patients achieved different degrees of improvement in the negative conversion ratios of e antigen,HBV-DNA and ALT,and the negative conversion ratios of e antigen,HBV-DNA in moderate and severe groups are apparently higher than mild group(P<0.05).Conclusion The moderate and severe e antigen-positive chronic hepatitis can get the best therapeutic effect of lamivudine in anti-HBV.更多还原